Altre lingue Pharvaris N.V.

Azioni

PHVS

NL00150005Y4

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 30/04/2024			Variaz. 5gg	Var. 1 gen.
24,59 ^USD	+4,86%		+15,50%	-12,34%

15/04	PHARVARIS N.V. : giudizio positivo da Morgan Stanley	ZM
10/04	Pharvaris riduce la perdita netta del quarto trimestre; assume un nuovo CFO	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Pharvaris Files Mixed Shelf	12/04
Pharvaris Narrows Q4 Net Loss; Hires New CFO	10/04
Pharvaris N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	10/04
Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	10/04
Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer	10/04
Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer	10/04
Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference	04/04
Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses	18/03
Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses	18/03
Pharvaris N : Poster	15/03
Pharvaris N : EGM Meeting Minutes	12/03
Pharvaris N : Results of Extraordinary General Meeting of Shareholders - Form 6-K	06/03
Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses	06/03
Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses	06/03
Pharvaris to Participate in the Leerink Global Biopharma Conference 2024	05/03
Pharvaris to Participate in the Leerink Global Biopharma Conference 2024	05/03
Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting	22/02
Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting	22/02
Pharvaris Announces Extraordinary Meeting of Shareholders	16/02
Pharvaris Announces Extraordinary Meeting of Shareholders	16/02

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Pharvaris N.V.

Azioni

PHVS

NL00150005Y4

Altre lingue

Filtri